[ Anglais] Lung Cancer Q&A: Is It Safe to Use an Immunotherapy After a Targeted Treatment?

Published on

Topics include: Treatments and Understanding

Lung cancer expert Dr. Jhanelle Gray, from Moffitt Cancer Center, gives an expert perspective on the recommended sequential approach to lung cancer treatment and explains what therapies are safe to combine so patients experience the least toxicity. Watch now to learn more about navigating lung cancer treatment options. 

This is a Patient Empowerment Network program produced by Patient Power, in partnership with Moffitt Cancer Center. We thank AbbVie, Inc., Celgene Corporation, Foundation Medicine, and Novartis for their support.

View more programs featuring and

Produced in association with and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:                     

Here’s a question we got from Jim. “How does immunotherapy work in EGFR mutations after targeted therapies no longer work?” Do you wanna comment?

Dr. Gray:                    

Yeah. Yeah. So, that’s a great question. So, one of the key things as I mentioned before is if you find a mutation such as the EGFR mutation you go down the realm of a targeted therapy. So, say to treat patients with a targeted therapy’s very, very important.

I wanna take this opportunity to say that you should not combine an EGFR inhibitor with an anti-PD1 with an immunotherapy. It significantly raises patient’s toxicity. So, if a physician ever—if that ever comes up, at least for right now, the answer, you should decline that, and no one should be offering that to you. Exactly.

So, I agree that the best way to incorporate them right now is through a sequential approach. So, you start with the EGFR inhibitor. And there’s four of them actually FDA-approved right now. So, you may get sequenced from one EGFR inhibitor to the next. What people are looking at right now is should we go straight to immunotherapy, should we go straight to chemotherapy, or should we go straight to a combination strategy of chemotherapy and immunotherapy?

I think based on the data for right now, most of us as long as we think that it’s safe will go to a combination of chemotherapy plus the immunotherapy based on the data. This is gonna be looked at more in detail to finally answer this question. It also depends on the wishes of the patients too. So, if you think that you cannot—if a patient cannot tolerate, for example, immunotherapy combination with chemotherapy, we may start with one or the other and then move on. But definitely I agree that the sequencing is gonna be the best way to do that.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Lung Cancer Q&A: What Are the Long-Term Side Effects of Chemo?

What can be the long-term effects of chemo? Lung cancer expert Dr. Jhanelle Gray explains how chemo can affect blood counts and how doctors can reduce side effects.

Published:

Lung Cancer Q&A: How Can Radiation Side Effects Be Reduced?

How do doctors balance treatment efficacy and side effects? Watch now to hear experts Dr. Stephen Rosenberg and Dr. Jhanelle Gray explain ways to lower radiation toxicities.

Published:

Lung Cancer Q&A: Any New Research or Treatment for Patients With the TP53 Mutation?

Are there any research developments for patients with the TP53 mutation? Watch now to hear from lung cancer experts Dr. Jhanelle Gray and Dr. Theresa Boyle.

Published:

Lung Cancer Q&A: How Accurate Are Blood Biopsy Results?

How reliable are blood biopsy results when looking at genetic mutations? Lung cancer expert Dr. Theresa Ann Boyle explains the pros and cons of testing and how to help ensure the most accuracy.

Published:

Lung Cancer Q&A: What Are Driver Mutations?

How do driver mutations influence lung cancer treatment decisions? Tune in to hear lung cancer experts Dr. Jhanelle Gray and Dr. Theresa Boyle explain how doctors identify unique tumor biology.

Published:

Lung Cancer Q&A: When Should Patients Consider Getting a Liquid Biopsy?

Where do liquid biopsies fit in with lung cancer care? Watch to hear lung cancer expert Dr. Theresa Boyle discuss liquid biopsy purpose, value and influence of test results.

Published:

Lung Cancer Q&A: Can Mutations Change Over Time?

How often should lung cancer patients get genetic testing? Can treatment cause mutational status to change? Watch and learn from lung cancer expert Dr. Jhanelle Gray.

Published:

Advertisement
Rejoignez notre communauté S'inscrire aux événements Lisez notre dernier blog
Advertisement

Page last updated on March 11, 2019